Study at a glance
Which active vitamin D substance did researchers study in intestinal tissue?
This laboratory study investigated a substance formed when the body changes vitamin D3. The substance had strong biological effects in the intestine, the part of the digestive system after the stomach. Researchers separated it from other substances in intestinal tissue. They wanted to identify its chemical structure. This was not a trial of vitamin D treatment in people.
How did the researchers identify this active form of vitamin D3?
Several laboratory tests identified the substance as 1,25-dihydroxycholecalciferol, an active form of vitamin D3. The tests examined its chemical structure, how it absorbed light and how it reacted with other chemicals. The results agreed with one another. The substance also separated differently from 25-hydroxycholecalciferol, another form of vitamin D. This supported the idea that vitamin D3 changes into distinct forms as it becomes active.
Did finding active vitamin D in the intestine show where it was made?
The study gave researchers a specific substance to investigate when studying vitamin D activity in the intestine. However, identifying that substance did not explain every step needed to produce it or how the body controls those steps. Finding it in intestinal tissue did not prove that the intestine had made it.
Does identifying active vitamin D establish its health benefits?
The study did not test health benefits, supplement doses or suitable vitamin D blood levels. It did not establish how responses vary between people. It also did not show how the active substance sends signals inside cells. Its main finding was the identity of the substance, not a complete explanation of vitamin D action.
Read the full article below ↓Evidence from a single verified primary scientific study evaluated using a fixed, auditable study-page structure. For the concise version, see Vitamin D3 Stepwise Conversion to the Active Hormone: Study Summary.
Study classification and identity
Study type: Primary biochemical isolation and structural identification study (metabolite purification and chemical characterisation)
Parent study or cohort: Not applicable
Ancillary analysis focus: Isolation and structural identification of 1,25-dihydroxycholecalciferol as an intestinally active vitamin D3 metabolite
Exposure type: Endogenous vitamin D3-derived intestinal metabolite(s) isolated from biological tissue after metabolic conversion
Comparison or grouping structure: Not applicable
Primary endpoint category: Chemical identity of the biologically active metabolite
Clinical endpoints assessed: None
Study purpose and framing
This study is designed to resolve a core “stepwise conversion” question in vitamin D3 physiology using direct biochemical evidence rather than inference: if vitamin D3 is introduced into a living system, what specific metabolite corresponds to the highly potent, biologically active factor acting in the intestine? The investigators treat vitamin D3 not as the final effector molecule but as an upstream input whose physiological meaning depends on metabolic conversion. The work focuses on a metabolite that had been observed in intestinal tissue as a distinct chromatographic entity with high biological potency and greater polarity than 25-hydroxycholecalciferol. The central purpose is to isolate that metabolite in a form suitable for definitive structural assignment, then establish whether its chemical identity supports a stepwise activation model culminating in a hormonally active form.
Importantly, the study frames its outcomes as an identity-and-characterisation deliverable rather than a clinical or therapeutic claim. The authors are not attempting to test whether vitamin D3 “works” for any endpoint in humans, nor are they attempting to map dose-response relationships, behavioural outcomes, or long-horizon clinical risks. Instead, the work aims to show that a specific metabolite exists as a discrete molecular species, can be isolated, and can be chemically identified using multiple independent analytical approaches. In this framing, “activity” refers to the biological potency associated with the metabolite in intestinal contexts, while the main scientific product is a verified structure that can anchor subsequent mechanistic and physiological interpretation.
The study also carries clear boundary conditions about what it does not attempt to resolve. It does not aim to describe the full network of vitamin D metabolism, enumerate every possible hydroxylated derivative, or establish tissue-by-tissue biosynthetic routing. It is not a comprehensive map of the entire endocrine system that vitamin D participates in, and it does not seek to quantify the relative contributions of different organs to production under different physiological states. Instead, it focuses narrowly on obtaining chemical proof of identity for the intestinally active metabolite, thereby converting a physiological hypothesis (“there is an active metabolite downstream of vitamin D3”) into a chemically grounded entity that can be referenced precisely in later research.
Why the primary measure is used as a biological marker
The primary “measure” in this paper is not a clinical biomarker in the modern sense, but a chemically defined identity for a metabolite associated with biological potency in intestinal tissue. The rationale is straightforward: without structural identification, any discussion of stepwise conversion remains vulnerable to ambiguity, because multiple sterols can co-elute, share partial spectral features, or be misattributed based on indirect assays. By isolating the metabolite and identifying it as 1,25-dihydroxycholecalciferol, the study provides a concrete molecular endpoint for the stepwise conversion pathway. In that sense, the identified metabolite becomes a marker of activation: it is the named chemical entity that represents “vitamin D3 after conversion” in its potent intestinally relevant form.
The interpretive guardrails are important. Chemical identification does not, by itself, specify the full physiological route of formation in every tissue, the regulatory hierarchy that controls the conversion, or the exact mechanism by which the metabolite produces its biological effects. It establishes identity, not complete causality. Even when the metabolite is described as “active,” the study’s main contribution is to show that the molecule exists and can be structurally assigned, enabling later work to separate questions of production (where and when it is made), distribution (how it reaches target cells), receptor engagement (how it signals), and physiological outputs (what downstream programs it alters).
Measurement constraints are also intrinsic to the era and the biochemical approach. The ability to identify the metabolite depends on sufficient purification, appropriate derivatisation where needed for analytical detection, and the use of converging chemical evidence (for example, mass spectrometric patterns, ultraviolet absorbance characteristics, and targeted chemical reactions). These methods provide strong identity claims when concordant, but they do not provide the same kind of population-level variability insight that modern cohort biomarker studies can. The core value here is specificity: the study replaces an undefined “peak” or “fraction” with a defined chemical structure that subsequent physiology can interpret more precisely.
General physiological context (not derived from this study): In contemporary vitamin D physiology, stepwise conversion is commonly described as conversion of vitamin D3 to 25-hydroxyvitamin D in the liver and then to 1,25-dihydroxyvitamin D (calcitriol) via regulated hydroxylation, with receptor-mediated signalling in target cells. This paper does not provide a full system map; its contribution is to anchor the “active form” component through primary chemical identification in an intestinal context.
Study overview
The study isolates a biologically active vitamin D3 metabolite from intestinal tissue, focusing on a metabolite that is more polar than 25-hydroxycholecalciferol and associated with strong biological potency in the intestine. The investigators pursue purification of the metabolite from complex biological mixtures, using chromatography and chemical derivatisation strategies suitable for obtaining a preparation amenable to structural analysis. The emphasis is on achieving sufficient purity and analytical tractability to make a confident structural assignment rather than relying on partial or indirect signals.
Because the study is primarily chemical, the “population” is best understood as the biological system from which tissue samples were obtained and processed. The approach depends on extracting lipid-soluble compounds from intestinal tissue and then separating them into fractions based on polarity and related chemical properties. The metabolite of interest is tracked across purification steps, and once sufficiently isolated, is subjected to analytical identification using multiple methods that can converge on a specific structure.
Operational definitions are set by the biochemical workflow. The metabolite is defined by its chromatographic behaviour (including its higher polarity relative to 25-hydroxycholecalciferol), its association with biological potency in intestinal contexts, and its analytical signature once purified. The endpoint is not an effect size in a clinical outcome, but a chemical identity claim supported by analytical evidence that the metabolite is 1,25-dihydroxycholecalciferol.
Study design and measurement approach
The design is an isolation-and-identification pipeline: obtain intestinal tissue containing vitamin D-related metabolites, extract the relevant lipid fractions, separate components using chromatographic methods, and progressively enrich the fraction corresponding to the biologically active, polar metabolite. A key feature of such a design is that the credibility of the final structural assignment depends on the integrity of the purification and the avoidance of co-eluting contaminants that could distort analytical readouts. The study therefore relies on a sequence of purification steps and a deliberate narrowing of material to a preparation that can be characterised with confidence.
Analytical identification uses a convergent evidence strategy. Rather than relying on a single signal, the metabolite’s structure is supported by mass spectrometric data (made feasible through appropriate derivatisation), ultraviolet absorption spectrophotometry, and specific chemical reactions consistent with the proposed hydroxylation pattern. The logic is cumulative: each method constrains the set of plausible structures, and agreement across methods increases certainty that the metabolite is correctly identified. The study thereby translates a physiological hypothesis into a chemically verified entity.
Timing and sampling cadence are not presented as longitudinal schedules in a clinical sense, because the purpose is structural identification. The relevant “cadence” is the progression through purification and analysis. At each stage, the metabolite is retained, enriched, and assessed until the investigators reach a point where direct identification methods can be applied. This is a classic approach when the target compound is present in low quantities and must be isolated from a complex mixture of related sterols.
Methodological trade-offs are inherent. Purification and derivatisation can introduce loss of material and may bias what is recoverable, but they enable analytical precision. Similarly, the approach yields high specificity for identity but does not directly quantify physiological regulation in vivo under varying conditions. The payoff is that the metabolite is no longer an anonymous “peak” but a defined molecule, allowing later studies to ask better-posed questions about regulation, tissue production, receptor binding, and downstream signalling.
Relevant physiology background: Vitamin D Activation.
Outcome hierarchy
Directly measured outcomes: Chemical identity of the isolated intestinally active vitamin D3 metabolite as 1,25-dihydroxycholecalciferol, supported by convergent analytical evidence
Outcomes explicitly not measured: Clinical endpoints; long-term health outcomes; population risk estimates; therapeutic efficacy; behavioural or symptomatic outcomes
Outcomes not inferable from this study: Population-level associations between vitamin D status and disease; causal effects of supplementation; tissue-wide regulatory hierarchies across all organs; dose-response thresholds for clinical practice
Statistical analysis
This study’s structure is primarily analytical and chemical rather than inferential-statistical. The core claims are established through identification methods that do not depend on hypothesis testing across large samples. Instead, the “analysis framework” is the chemical logic of structural elucidation: the metabolite’s identity must be consistent across independent analytical modalities, and the evidence must converge on a single plausible structure. In that sense, the strength of the result is not expressed as a p-value but as concordance across measurement methods.
Covariates, adjustments, and stratification typical of epidemiologic studies are not central here because the goal is not to estimate associations under confounding. The relevant controls are methodological: ensuring that purification steps isolate the compound of interest, that derivatisation produces interpretable analytical signatures, and that the observed spectra and chemical reactions match those expected for the proposed hydroxylated structure. The study’s credibility therefore rests on analytical specificity and internal methodological consistency.
Handling of missing data is also not framed in a modern statistical sense. The risks are instead practical: loss of compound during purification, contamination, or insufficient yield for high-confidence identification. The investigators address these by deriving an analyzable preparation and applying multiple identification methods so that a single ambiguous signal cannot carry the identity claim alone.
Effect size framing is therefore qualitative and evidentiary: the metabolite is identified, and its identity supports the concept of an activated vitamin D3 form relevant to intestinal physiology. Importantly, this does not imply that the study quantifies the magnitude of physiological effects in vivo, nor does it imply that this single paper establishes the entire pathway’s regulation. It establishes a key chemical fact that is necessary for coherent physiological interpretation of stepwise conversion.
Results
The primary result is the successful isolation of a highly polar, biologically active vitamin D3 metabolite from intestinal tissue and its identification as 1,25-dihydroxycholecalciferol. The identification is supported by mass spectrometry (enabled by derivatisation suitable for the analytical method), ultraviolet absorption characteristics, and specific chemical reactions consistent with the proposed hydroxylation pattern. The result converts the concept of an “active intestinal metabolite” from an operational fraction into a named chemical structure that can be referenced precisely.
Secondary results are embedded in the analytical narrative: the metabolite behaves distinctly from 25-hydroxycholecalciferol in chromatographic separation (consistent with increased polarity), and the analytical signatures align with a dihydroxylated structure rather than a mono-hydroxylated derivative. These observations matter because they support a stepwise model in which vitamin D3 undergoes sequential modifications, producing metabolites with different physical properties and, by implication, different biological roles.
Null results are not presented as statistical non-associations, but the work implicitly rules out alternative identities that would be inconsistent with the combined analytical evidence. The value of the convergent approach is precisely that it narrows the plausible identity set. If the mass spectral fragments, UV absorbance, and chemical reaction behaviour were inconsistent, the identity claim would weaken; the study’s success rests on the alignment of these independent methods.
Study-reported caveats are naturally tied to biochemical isolation work: the interpretation hinges on purity, correct derivatisation, and correct reading of analytical signatures. However, by relying on multiple methods rather than a single assay, the authors strengthen internal consistency. The output is therefore best understood as a strong chemical identity claim rather than a broad physiological conclusion about all aspects of vitamin D3 action.
Measurement considerations and limitations
The main measurement considerations involve compound purity and analytical specificity. In complex biological extracts, closely related sterols may co-elute or partially overlap in chromatography, and trace contamination can confound spectral readings. The study addresses this by purifying the metabolite to a form suitable for structural analysis and then using multiple analytical approaches to triangulate identity. Even so, the quality of the conclusion depends on successful isolation and accurate interpretation of analytical outputs.
Representativeness is limited in the sense that the study does not attempt to characterise variability across diverse populations or physiological states. It provides a biochemical fact about identity under the conditions studied. The question of how commonly, how rapidly, and under what regulatory controls the metabolite is produced is not resolved by this design. Therefore, generalisation is best framed as “this metabolite exists and can be identified as 1,25-dihydroxycholecalciferol,” not as “this metabolite behaves the same way across all contexts.”
Confounding and reverse causality risks, as used in observational epidemiology, are not the primary limitations here. Instead, the key limitations are those of chemical workflow: yield constraints, potential artefact formation during derivatisation, and reliance on analytical instrumentation capabilities of the period. The study’s strength is that it establishes identity despite these constraints, but it should not be stretched into claims about clinical causality or population-level effects.
Generalisability and population context
The primary generalisable element is the chemical identity assignment: 1,25-dihydroxycholecalciferol can be isolated as a discrete metabolite associated with intestinal biological activity. This provides a stable reference point for physiology. It allows later work to connect the concept of “activation” to a specific molecule and to test how production varies with organ function, mineral balance, endocrine signalling, and tissue-specific enzyme expression.
However, extrapolation beyond chemical identity is not valid. The study does not establish how the metabolite’s concentration varies across individuals, how it responds dynamically to environmental inputs, or how it integrates with broader endocrine control. It also does not establish that any given blood measurement is a sufficient proxy for tissue-level activity. Those are distinct questions that require different study designs.
The contextual factors that limit transferability are therefore mainly methodological and scope-based: the metabolite is identified under the conditions studied, and the result supports stepwise conversion, but it does not specify the full physiological routing, tissue distribution, or receptor-mediated programme engagement in different populations. The study is an enabling piece of evidence, not a complete systems explanation.
Mechanistic inference boundary
The mechanistic boundary here is sharp. Identifying 1,25-dihydroxycholecalciferol as the metabolite active in intestinal contexts supports a stepwise conversion model, but it does not by itself explain the signalling mechanism by which the metabolite produces downstream effects. Mechanism in the receptor and transcriptional sense requires additional evidence about binding to the vitamin D receptor, nuclear localisation, gene regulation, and downstream cellular responses. This paper’s contribution is upstream of that: it defines the molecule that mechanistic work should focus on.
What cannot be concluded from this study includes: that vitamin D3 input always results in the same tissue concentrations of 1,25-dihydroxycholecalciferol; that blood levels of any metabolite directly quantify tissue-level signalling; that changes in metabolite presence necessarily cause any particular clinical outcome; or that supplementation strategies are implied. These are separate questions that require controlled physiological studies and, where relevant, clinical designs.
Crucially, identification of an “active form” should not be conflated with an assertion that all downstream physiological outcomes are determined solely by that molecule in isolation. Physiological effects depend on receptor expression, co-regulator availability, local enzyme activity, substrate availability, and tissue context. This study defines the active molecule, but it does not define the whole context in which that molecule operates. The proper inference is therefore: stepwise conversion produces a distinct dihydroxylated metabolite that can be chemically identified and treated as the activated form relevant to intestinal physiology.
Relevant signalling background: Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).
Interpretation within vitamin D physiology
Within the physiology of how vitamin D3 works, this study supports the conceptual shift from “vitamin D3 as the direct actor” to “vitamin D3 as a precursor whose function is realised through conversion into a hormonally active form.” The identification of 1,25-dihydroxycholecalciferol as an intestinally active metabolite provides a concrete endpoint for the conversion chain: vitamin D3 can be metabolically transformed into a specific dihydroxylated molecule that is chemically distinct, more polar than upstream hydroxylated forms, and associated with high biological potency in intestinal contexts. This anchors the stepwise conversion narrative to a named compound, enabling clearer thinking about where regulation may occur (at conversion steps), how tissues may differ (via local enzyme activity), and why “vitamin D status” and “vitamin D effect” can diverge in real systems.
For relevant physiology background, see How Vitamin D3 Works.
Relevant receptor or response background: Vitamin D Receptors.
Historical scientific context of the research question
The research question reflects a period when vitamin D physiology was transitioning from a nutrient-deficiency framing to an endocrine-metabolite framing. Biological assays suggested that certain tissue fractions had strong activity, but without chemical identity, competing interpretations could persist: some could attribute effects to vitamin D3 itself, others to an unknown derivative, and still others to mixtures of metabolites. The problem was not simply academic; without identity, it was impossible to build a coherent sequence of conversion steps or to assign responsibility to specific enzymes and tissues. By pursuing purification and structural analysis, the study participates in a broader scientific transition: moving from “activity observed” to “molecule defined,” which is a prerequisite for later work on biosynthetic control and receptor-mediated action.
Prevailing assumptions implicitly tested
A key implicit assumption tested is that the most biologically potent intestinal activity associated with vitamin D physiology corresponds to a distinct metabolite rather than the parent compound. Another assumption is that chromatographic “peaks” linked to activity are not merely artefacts or mixtures but can be purified into single molecular entities with stable analytical signatures. The work also implicitly tests whether polarity differences observed in metabolic fractions meaningfully reflect different hydroxylation states and thus different positions in a conversion chain. Confirmation of a dihydroxylated identity supports the idea that multiple sequential modifications are part of the activation story.
Design scope choices and alternatives not pursued
The study chooses depth of chemical certainty over breadth of physiological mapping. It does not attempt to quantify production rates under different endocrine conditions, compare multiple organs simultaneously, or follow time courses across many physiological perturbations. Alternative designs could have aimed to correlate metabolite presence with physiological states, but those would still have suffered from identity ambiguity. The authors’ choice is therefore strategic: secure identity first, then allow later studies to build the regulatory and functional architecture around a defined molecule. This scope choice makes the paper foundational rather than comprehensive.
Likely over-interpretations and misreadings
A common over-reading would be to treat chemical identification as proof of complete mechanism or proof of clinical relevance. The study does not demonstrate receptor binding, gene regulation, or the downstream cascade of physiological outputs. Nor does it prove that any particular intake strategy produces predictable effects in humans. Another misreading would be to assume that because the metabolite is identified in an intestinal context, intestinal cells must be the dominant site of its formation; the design does not establish tissue-of-origin, only tissue-of-isolation and identity. The correct interpretation is narrower: the active metabolite exists and is 1,25-dihydroxycholecalciferol.
Questions the study appears relevant to but cannot answer
The study is relevant to questions about where the active hormone is produced, how tightly production is regulated, and how tissue-specific conversion influences signalling. However, it cannot answer which organ is the dominant producer under different physiological conditions, how circulating levels relate to local intracrine conversion, or how receptor density and co-regulator context shape functional outputs. It also cannot resolve how vitamin D metabolite dynamics vary across season, diet, genetics, or disease states, because those questions require population and systems-level designs.
Residual uncertainties left unresolved
Even with identity established, uncertainties remain about regulation, routing, and context. How is production controlled in vivo? Which enzymes and tissues govern the final activation step under varying calcium or endocrine conditions? How do degradation pathways constrain signalling duration? What is the relationship between circulating metabolites and tissue-specific concentrations? This paper does not attempt to close those questions, but it clarifies them: once the active molecule is known, uncertainties can be posed in more precise biochemical and physiological terms.
Interpretation
Supported interpretation only: This primary study provides biochemical evidence that a highly potent intestinally relevant vitamin D3 metabolite can be isolated and structurally identified as 1,25-dihydroxycholecalciferol. That identity supports a stepwise conversion framework in which vitamin D3 functions as a precursor whose physiological “activity” is realised through conversion into a distinct, dihydroxylated metabolite. The contribution is therefore foundational: it defines the molecular endpoint that later mechanistic and regulatory studies can examine, rather than offering a complete explanation of signalling or clinical outcomes.
Boundary restatement: The study does not establish clinical benefit, does not quantify population-level variability, and does not demonstrate receptor-mediated genomic programmes within the same experimental frame. It also does not prove tissue-of-origin or regulatory hierarchy for the conversion steps. It is best understood as a chemical identification milestone that makes subsequent claims testable and specific. Overreach would be to convert this identity result into dosing guidance, disease claims, or broad predictive models of individual response.
Measured versus contextual restatement: The measured result is the chemical identity of the isolated metabolite and the analytical evidence supporting that identity. The contextual physiology is the broader stepwise model and the endocrine framework that later research develops around 1,25-dihydroxycholecalciferol. This paper enables that context by providing a defined molecule to anchor interpretation, but it does not itself supply the full physiological narrative beyond the identity-supported implication that conversion is essential to “how vitamin D3 works.”
Primary source and publication details
Holick MF, Schnoes HK, DeLuca HF, et al.
Isolation and identification of 1,25-dihydroxycholecalciferol. A metabolite of vitamin D active in intestine.
Biochemistry. 1971.
DOI: 10.1021/bi00790a023
https://pubmed.ncbi.nlm.nih.gov/4326883
Related reading
Vitamin D3 Stepwise Conversion to the Active Hormone: Study Summary
A structured study summary explaining the stepwise conversion of vitamin D3 into its active hormonal form, including key metabolic stages and biological context.
Read more →From Vitamin D3 to Active Hormone: Connecting the Activation Pathway
Explore how vitamin D3 becomes active vitamin D through hepatic and renal metabolism, endocrine regulation and extra-renal activation in peripheral cells.
Read more →1α,25-Dihydroxyvitamin D3 Improves Follicular Development and Steroid Hormone Biosynthesis by Regulating Vitamin D Receptor in the Layers Model
This study investigated, through in vivo and in vitro experiments, the effects of VitD3 on follicle development and steroid hormone biosynthesis in young layers.
Original paper ↗Read more →Anti-inflammatory 25(OH)D3, a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia
Differentiation syndrome (DS) is a serious complication with an unclear pathogenesis that arises following all-trans retinoic acid (ATRA) or arsenic trioxide induction therapy in acute promyelocytic leukemia (APL).
Original paper ↗Read more →Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium
Here, we assessed whether 41 SNPs within steroid hormone genes associated with erosive disease.
Original paper ↗Read more →Hepatic CYP2R1 and Vitamin D Conversion: Full Study
How CYP2R1 converts vitamin D: human genetic evidence, mouse liver experiments, metabolic regulation and the limits of interpreting blood 25(OH)D.
Read more →Routine Vitamin and Iron Biomarkers Do Not Explain Variation in Anti-Müllerian Hormone: Implications for Ovarian Reserve Testing in Clinical Practice
Anti-Müllerian hormone (AMH) is a key biomarker of ovarian reserve, reflecting the quantity of the remaining follicular pool.
Original paper ↗Read more →Vitamin D and Phosphate: Hormone Feedback, Bone and Energy: Full Evidence Review
How vitamin D, FGF23 and PTH regulate phosphate, and what human and animal studies show about bone mineralisation and muscle energy.
Read more →Changes in the vitamin D endocrine system and bone turnover after oral vitamin D3 supplementation in healthy adults: results of a randomised trial
We aimed to investigate whether four weeks’ daily supplementation with 10 μg vitamin D3 from fish oil produced a greater change in serum vitamin D metabolites, parathyroid hormone, and bone turnover in healthy adults compared with solid multivitamin tablets.
Original paper ↗Read more →Evidence of a dysregulated vitamin D endocrine system in SARS-CoV-2 infected patient’s lung cells
To understand the significance of the vitamin D endocrine system in SARS-CoV-2 pathobiology, computational approaches were applied to transcriptomic datasets from bronchoalveolar lavage fluid (BALF) cells of such patients or healthy individuals.
Original paper ↗Read more →The Preventive Role of the Vitamin D Endocrine System in Cervical Cancer
Several studies have found an inverse relationship between the incidence of cervical neoplasia and vitamin D levels.
Original paper ↗Read more →Vitamin D Endocrine System and COVID‐19
This needs to be confirmed by large, randomized trials, but in the meantime, we recommend (rapid) correction of 25 hydroxyvitamin D (25OHD) deficiency in subjects exposed to this coronavirus.
Original paper ↗Read more →Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol
The COVID-19 pandemic is the greatest challenge facing modern medicine and public health systems.
Original paper ↗Read more →Vitamin D and Endocrine Crosstalk
Explains how vitamin D interacts with other hormone systems through endocrine crosstalk, including links with calcium regulation, stress hormones, sex hormones, and metabolic signalling, without making treatment or dosage claims.
Read more →Vitamin D and Endocrine Coordination: Compensation and Failure: Full Study
Explore tissue-specific vitamin D and FGF23 experiments, mineral compensation and the limits of linking metabolic and stress-related endocrine findings.
Read more →Vitamin D and Endocrine Coordination: Compensation and Failure: Study Summary
A concise account of mineral compensation, FGF23 disruption and conditional metabolic and glucocorticoid findings across the selected studies.
Read more →Maternal Vitamin D Adaptations During Pregnancy: Full Evidence Review
How pregnancy affects active, total and free vitamin D.
Read more →Vitamin D, Mucosal Surveillance and Local Gut and Airway Defence: Full Evidence Review
Local vitamin D activation, antimicrobial responses and gut-airway differences, with animal contradictions and human respiratory-trial limitations.
Read more →Vitamin D-Responsive Gene Expression Across Cells and Tissues: Full Evidence Review
Compare vitamin D-responsive transcription in cells, organoids and human blood, with distinctions between acute signals, longer trials and tissue outcomes.
Read more →Vitamin D, T-Cell Differentiation and Regulatory Balance: Study Summary
Plain-English summary of human T-cell studies: vitamin D responses and why laboratory regulation does not prove lasting immune tolerance.
Read more →Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D
A physiology-first explanation of vitamin D testing, comparing 25-OH-D and 1,25-OH₂-D and how each marker should be interpreted within regulated biological systems.
Read more →Original sources
https://pubmed.ncbi.nlm.nih.gov/4326883
https://pubmed.ncbi.nlm.nih.gov/4326883.
Publication details
https://pubmed.ncbi.nlm.nih.gov/4326883